Systemic therapy for advanced hepatocellular carcinoma: a review

Ferlay J, Bray F, Pisani P, Parkin DM. In: GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide. Version 1.0 ed. IARC Cancer Base No. 5. Lyon: IARC Press; 2001 Bosch, 1997, Global epidemiology of hepatocellular carcinoma, 13 Yang, 2002, Hepatitis B e antigen and the risk of hepatocellular carcinoma, NEJM, 347, 168, 10.1056/NEJMoa013215 Tsukuma, 1993, Risk factors for hepatocellular carcinoma among patients with chronic liver disease, NEJM, 328, 1797, 10.1056/NEJM199306243282501 El-Serag, 1999, Rising incidence of hepatocellular carcinoma in the United States, NEJM, 340, 745, 10.1056/NEJM199903113401001 Colombo, 1989, Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma, Lancet, 2, 1006, 10.1016/S0140-6736(89)91016-7 Fong, 1999, An analysis of 412 cases of hepatocellular carcinoma at a Western center, Ann. Surg., 229, 790, 10.1097/00000658-199906000-00005 Johnson, 2002, Hepatocellular carcinoma: is current therapy really altering outcome, Gut, 51, 459, 10.1136/gut.51.4.459 Groupe d'Etude et de Traitment du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. NEJM 1995;332(19):1256–61 Balsells, 1996, Resection of hepatocellular carcinoma in patients with cirrhosis, Br. J. Surg., 83, 758, 10.1002/bjs.1800830610 Llovet, 2003, Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival, Hepatology, 37, 429, 10.1053/jhep.2003.50047 Chan, 2003, Neoadjuvant and adjuvant therapy for operable hepatocellular carcinoma (Cochrane Review) Mathurin, 2003, Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma, Aliment. Pharmacol. Ther., 17, 1247, 10.1046/j.1365-2036.2003.01580.x Huang, 1992, Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma, J. Natl. Cancer Inst., 84, 262, 10.1093/jnci/84.4.262 Chou, 1997, Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical correlation, J. Gastroeterol. Hepatol., 12, 569, 10.1111/j.1440-1746.1997.tb00487.x Olweny, 1975, Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication, Cancer, 36, 1250, 10.1002/1097-0142(197510)36:4<1250::AID-CNCR2820360410>3.0.CO;2-X Vogel, 1977, A phase II study of adriamycin (NSC 123127) in patients with hepatocellular carcinoma from Zambia and the United States, Cancer, 39, 1923, 10.1002/1097-0142(197705)39:5<1923::AID-CNCR2820390502>3.0.CO;2-2 Johnson, 1978, Induction of remission in hepatocellular carcinoma with doxorubicin, Lancet, 1, 1006, 10.1016/S0140-6736(78)90735-3 Oon, 1980, Adriamycin in the treatment of resectible and irresectible primary hepatocellular carcinoma, Ann. Acad. Med. Singapore, 9, 256 Falkson, 1978, Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial, Cancer, 42, 2149, 10.1002/1097-0142(197811)42:5<2149::AID-CNCR2820420510>3.0.CO;2-5 Choi, 1984, Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy, Cancer, 53, 401, 10.1002/1097-0142(19840201)53:3<401::AID-CNCR2820530306>3.0.CO;2-L Melia, 1983, Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin, Cancer, 51, 206, 10.1002/1097-0142(19830115)51:2<206::AID-CNCR2820510206>3.0.CO;2-P Chlebowski, 1984, Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results, Cancer Treat. Rep., 68, 487 Sciarrino, 1985, Adriamycin treatment for hepatocellular carcinoma Experience with 109 patients, Cancer, 56, 2751, 10.1002/1097-0142(19851215)56:12<2751::AID-CNCR2820561205>3.0.CO;2-O Johnson, 1992, Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters, Br. J. Cancer, 65, 751, 10.1038/bjc.1992.158 Colombo, 1985, Hepatocellular carcinoma in Italy: report of a clinical trial with intravenous doxorubicin, Liver, 5, 336, 10.1111/j.1600-0676.1985.tb00256.x Lai, 1988, Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial, Cancer, 62, 479, 10.1002/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L Mathurin, 1998, Review article: overview of medical treatments in unresectable hepatocellular carcinoma – an impossible meta-analysis, Aliment. Pharmacol. Ther., 12, 111, 10.1046/j.1365-2036.1998.00286.x Cheng, 1998, Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma, Hepatogastroenterology, 45, 1955 Schachschal, 2000, Controlled clinical trial of doxorubicin and tamoxifen versus tamoxifen monotherapy in hepatocellular carcinoma, Eur. J. Gastroenterol. Hepatol., 12, 281, 10.1097/00042737-200012030-00004 Hong, 2003, A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma, Cancer Chemother. Pharmacol., 51, 433, 10.1007/s00280-003-0583-2 Daniele, 2000, Phase I clinical trial of liposomal daunorubicin in hepatocellular carcinoma complicating liver cirrhosis, Anticancer Res., 20, 1249 Halm, 2000, A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma, Ann. Oncol., 11, 113, 10.1023/A:1008386822906 Schmidinger, 2001, Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma, Br. J. Cancer, 85, 1850, 10.1054/bjoc.2001.2149 Yeo, 1999, Phase II studies with DaunoXome in patients with nonresectable hepatocellular carcinoma: clinical and pharmacokinetic outcomes, Cancer Chemother. Pharmacol., 44, 124, 10.1007/s002800050956 Ruff, 2001, Long term follow-up of pegylated liposomal doxorubicin (Caelyx): a well tolerated and effective agent in advanced hepatocellular carcinoma (HCC, Proc. Annu. Meet. Am. Soc. Clin. Oncol., 20 Morstyn, 1983, Combination chemotherapy of hepatocellular carcinoma with doxorubicin and streptozotocin, Am. J. Clin. Oncol., 6, 547, 10.1097/00000421-198310000-00006 Chlebowski, 1981, Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: clinical and pharmacokinetic aspects, Cancer, 48, 1088, 10.1002/1097-0142(19810901)48:5<1088::AID-CNCR2820480507>3.0.CO;2-W Falkson, 1999, A phase II evaluation of clofazimine plus doxorubicin in advanced, unresectable primary hepatocellular carcinoma, Oncology, 57, 232, 10.1159/000012036 Yang, 2002, Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I–II trial, Ann. Oncol., 13, 1771, 10.1093/annonc/mdf303 Tan, 1986, 4′-Epidoxorubicin (Epirubicin) as a single agent in advanced primary hepatocellular carcinoma – a preliminary experience, Ann. Acad. Med. Singapore, 15, 169 Hochster, 1985, 4′-Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma, J. Clin. Oncol., 3, 1535, 10.1200/JCO.1985.3.11.1535 Pohl, 2001, Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma, Chemotherapy, 47, 359, 10.1159/000048544 Raderer, 1996, A phase I/II trial of epirubicin and high dose tamoxifen as a potential modulator of multidrug resistance in advanced hepatocellular carcinoma, Eur. J. Cancer, 32A, 2366, 10.1016/S0959-8049(96)00280-8 Bobbio-Pallavicini, 1997, Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study, Eur. J. Cancer, 33, 1784, 10.1016/S0959-8049(97)00163-9 Huang, 2000, Prospective case-controlled trial of adjuvant chemotherapy after resection of hepatocellular carcinoma, World J. Surg., 24, 551, 10.1007/s002689910090 Lai, 1998, Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial, Arch. Surg., 133, 183, 10.1001/archsurg.133.2.183 Dunk, 1985, Mitozantrone as single agent therapy in hepatocellular carcinoma. A phase II study, J. Hepatol., 1, 395, 10.1016/S0168-8278(85)80777-7 Colleoni, 1992, Mitoxantrone in patients affected by hepatocellular carcinoma with unfavorable prognostic factors, Oncology, 49, 139, 10.1159/000227027 Lai, 1989, Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection, Cancer Chemother. Pharmacol., 23, 54, 10.1007/BF00258459 Falkson, 1995, Hepatocellular carcinoma: an ECOG randomized phase II study of beta- interferon and menagoril, Am. J. Clin. Oncol.: Cancer Clin. Trials, 18, 287, 10.1097/00000421-199508000-00003 Tumolo, 2002, Oral idarubicin for the treatment of hepatocellular carcinoma, Proc. Annu. Meet. Am. Soc. Clin. Oncol. Tetef, 1995, 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial, Cancer Invest., 13, 460, 10.3109/07357909509024907 Link, 1977, 5-Flourouracil in hepatocellular carcinoma: report of twenty-one cases, Cancer, 39, 1936, 10.1002/1097-0142(197705)39:5<1936::AID-CNCR2820390504>3.0.CO;2-N Porta, 1995, 5-Fluorouracil and d,l-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: preliminary results of a phase II study, Oncology, 52, 487, 10.1159/000227516 Gebbia, 1999, 5-Fluorouracil plus high dose levofolinic acid and oral hydroxyurea for the treatment of primary hepatocellular carcinomas: results of a phase II multicenter study of the Southern Italy Oncology Group (G.O.I.M), Anticancer Res., 19, 1407 Baker, 2000, Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil, J. Clin. Oncol., 18, 915, 10.1200/JCO.2000.18.4.915 Benson, 2002, Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma, Ann. Oncol., 13, 576, 10.1093/annonc/mdf079 Llovet, 2001, A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma, Eur. J. Cancer, 37, 1352, 10.1016/S0959-8049(01)00100-9 Mani, 1998, Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced hepatocellular carcinoma, Invest. New Drugs, 16, 279, 10.1023/A:1006104217137 Ishikawa, 2001, Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma, J. Gastroenterol. Hepatol., 16, 452, 10.1046/j.1440-1746.2001.02352.x Yamamoto, 1996, Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma, Br. J. Surg., 83, 336, 10.1002/bjs.1800830313 Lozano, 2000, Oral capecitabine (Xeloda) for the treatment of hepatobiliary cancers (hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer, Proc. Annu. Meet. Am. Soc. Clin. Oncol. Chun, 2003, A combination of capecitabine and thalidomide in patients with unresectable, recurrent or metastatic hepatocellular carcinoma, Proc. Annu. Meet. Am. Soc. Clin. Oncol. Tanioka, 2003, Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma, Anticancer Res., 23, 1891 Ellis, 1995, Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours, Eur. J. Cancer, 31A, 1594, 10.1016/0959-8049(95)00323-B Boucher, 2002, Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen), Cancer Chemother. Pharmacol., 50, 305, 10.1007/s00280-002-0503-x Leung, 2002, Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and5-fluorouracil chemotherapy, Cancer, 94, 421, 10.1002/cncr.10236 Kajanti, 1991, Phase II intravenous study of epirubicin with 5-fluorouracil in patients with advanced hepatocellular carcinoma, Eur. J. Cancer, 27, 1620, 10.1016/0277-5379(91)90428-G Al-Idrissi, 1985, Primary hepatocellular carcinoma in the eastern province of Saudi Arabia: treatment with combination chemotherapy using 5-fluorouracil, Adriamycin and mitomycin-C, Hepatogastroenterology, 32, 8 Lin, 2000, Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species, Cancer, 89, 983, 10.1002/1097-0142(20000901)89:5<983::AID-CNCR7>3.0.CO;2-G Chao, 1998, Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients, Br. J. Cancer, 78, 34, 10.1038/bjc.1998.438 Strumberg, 1998, Phase I study of a weekly 1 h infusion of paclitaxel in patients with unresectable hepatocellular carcinoma, Eur. J. Cancer, 34, 1290, 10.1016/S0959-8049(98)00054-9 Matsuoka, 1995, Cytotoxicity of CPT-11 for gastrointestinal cancer cells cultured on fixed-contact-sensitive plates, Anticancer Drugs, 6, 413, 10.1097/00001813-199506000-00008 Chu, 1998, Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters, Cancer Res., 58, 5137 O'Reilly, 2001, A phase II study of irinotecan in patients with advanced hepatocellular carcinoma, Cancer, 91, 101, 10.1002/1097-0142(20010101)91:1<101::AID-CNCR13>3.0.CO;2-K Boige, 2002, A multicenter phase II study of irinotecan (CPT-11) in patients with advanced hepatocellular carcinoma, Proc. Annu. Meet. Am. Soc. Clin. Oncol. Lee, 2003, Phase II study to topotecan and cisplatin in advanced hepatocellular carcinoma, Korean J. Intern. Med., 18, 104, 10.3904/kjim.2003.18.2.104 Alexandre, 2002, Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients, Am. J. Clin. Oncol., 25, 198, 10.1097/00000421-200204000-00021 Cavalli, 1981, Phase II study of oral VP-16-213 in hepatocellular carcinoma, Eur. J. Cancer Clin. Oncol., 17, 1079, 10.1016/0014-2964(81)90291-7 Wierzbicki, 1994, Phase II trial of chronic daily VP-16 administration in unresectable hepatocellular carcinoma (HCC, Ann. Oncol., 5, 466, 10.1093/oxfordjournals.annonc.a058882 Shiu, 1987, Phase 2 study of high dose etoposide (VP16-213) in hepatocellular carcinoma, Jpn. J. Clin. Oncol., 17, 113 Yoshino, 1989, A phase II study of etoposide in patients with hepatocellular carcinoma by the Tokyo Liver Cancer Chemotherapy Study Group, Jpn. J. Clin. Oncol., 19, 120 Cheng, 1996, Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma, Cancer, 77, 872, 10.1002/(SICI)1097-0142(19960301)77:5<872::AID-CNCR10>3.0.CO;2-0 Graziadei, 1998, Antitumor effect of the nucleoside analogs 2-chlorodeoxyadenosine and 2′,2′-difluorodeoxycytidine on human hepatoma HepG2 cells, J. Hepatol., 28, 504, 10.1016/S0168-8278(98)80326-7 Yang, 2000, Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma, Cancer, 89, 750, 10.1002/1097-0142(20000815)89:4<750::AID-CNCR5>3.0.CO;2-R Ulrich-Pur, 2001, Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine, Oncology, 60, 313, 10.1159/000058526 Kubicka, 2001, Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas, Hepatogastroenterology, 48, 783 Fuchs, 2002, A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma, Cancer, 94, 3186, 10.1002/cncr.10607 Yang, 2003, A phase II study of gemcitabine and cisplatin for patients with advanced hepatocellular carcinoma, Proc. Annu. Meet. Am. Soc. Clin. Oncol. Fuloria, 2000, A multicentre, phase II trial of gemcitabine and cisplatin in unresectable hepatocellular carcinoma, Proc. Annu. Meet. Am. Soc. Clin. Oncol. Lozano, 2003, Gemcitabine, amifostine and cisplatin, (GAP) for treatment of hepato-biliary cancer: a retrospective analysis in 50 patients, Proc. Annu. Meet. Am. Soc. Clin. Oncol. Okada, 1993, A phase 2 study of cisplatin in patients with hepatocellular carcinoma, Oncology, 50, 22, 10.1159/000227142 Stuart, 1999, A Phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma, Cancer, 86, 410, 10.1002/(SICI)1097-0142(19990801)86:3<410::AID-CNCR8>3.0.CO;2-P Mok, 1999, A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma, Cancer Chemother. Pharmacol., 44, 307, 10.1007/s002800050982 Hamburg, 2003, Survival benefit of nolatrexed in advanced hepatocellular carcinoma, Proc. Annu. Meet. Am. Soc. Clin. Oncol. Stuart, 2003, Phase II trial of irofulven in patients with unresectable hepatocellular carcinoma (HCC), Proc. Annu. Meet. Am. Soc. Clin. Oncol. Izzo, 2003, Phase I/II testing of pegylated arginine deaminase in subjects with hepatocellular carcinoma, Proc. Annu. Meet. Am. Soc. Clin. Oncol. Singh, 2003, Phase II trial of the epothilone B analog BMS-247550 in patients with hepatobiliary cancer, Proc. Annu. Meet. Am. Soc. Clin. Oncol., 22, 281 Reubi, 1995, Multiple actions of somatostatin in neoplastic disease, Trends Pharmacol. Sci., 16, 110, 10.1016/S0165-6147(00)88992-0 Reubi, 1999, Regulatory peptide receptors in human hepatocellular carcinomas, Gut, 45, 766, 10.1136/gut.45.5.766 Rabinowitz, 2002, Octreotide scans are positive in a subset of patients with hepatocellular carcinoma, Clin. Nuc. Med., 27, 499, 10.1097/00003072-200207000-00007 Kouroumalis, 1998, Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study, Gut, 42, 442, 10.1136/gut.42.3.442 Dimitroulopoulos, 2002, The role of sandostatin LAR in treating patients with advanced hepatocellular cancer, Hepatogastroenterology, 49, 1245 Samonakis, 2002, Treatment of hepatocellular carcinoma with long acting somatostatin analogues, Oncol. Rep., 9, 903 Yuen, 2002, A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma, Hepatology, 36, 687, 10.1053/jhep.2002.35071 Rabe, 2002, Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide, Z. Gastroenterol., 40, 395, 10.1055/s-2002-32129 Raderer, 2000, Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo, Int. J. Oncol., 16, 1197 Villa, 2002, Variant estrogen receptors and their role in liver disease, Mol. Cell Endocrinol., 193, 65, 10.1016/S0303-7207(02)00097-7 Chow, 2002, High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial, Hepatology, 36, 1221, 10.1053/jhep.2002.36824 Chao, 1997, Phase II study of megestrol acetate in the treatment of hepatocellular carcinoma, J. Gastroeterol. Hepatol., 12, 277, 10.1111/j.1440-1746.1997.tb00421.x Colombo, 1991, Hepatocellular carcinoma in Italian patients with cirrhosis, NEJM, 325, 675, 10.1056/NEJM199109053251002 Jonas, 1997, Female sex hormone receptor status in advanced hepatocellular carcinoma and outcome after surgical resection, Surgery, 121, 456, 10.1016/S0039-6060(97)90317-2 Nagasue, 1990, Specificity of androgen receptors of hepatocellular carcinoma and liver in humans, Hepatogastroenterology, 37, 474 Martinez Cerezo, 1994, Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma, J. Hepatol., 20, 702, 10.1016/S0168-8278(05)80138-2 Melia, 1987, Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma, Cancer Treat. Rep., 71, 1213 Farinati, 1992, Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma, Dig. Dis. Sci., 37, 659, 10.1007/BF01296419 Farinati, 1990, Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen, J. Hepatol., 11, 297, 10.1016/0168-8278(90)90211-9 Elba, 1994, Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma, Ital. J. Gastroenterol., 26, 66 Coll, 1995, Treatment with tamoxifen in patients with advanced hepatocellular carcinoma. Results of a randomized placebo controlled trial, Hepatology, 4, 404A, 10.1016/0270-9139(95)95338-8 Castells, 1995, Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients, Gastroenterology, 109, 917, 10.1016/0016-5085(95)90402-6 Liu, 2000, Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study, Am. J. Gastroenterol., 95, 218, 10.1111/j.1572-0241.2000.01688.x Barbare J-C, Milan C, Bouché O, et al. Treatment of advanced hepatocellular carcinoma (HCC) with tamoxifen: a phase III trial in 420 patients. In: Proc ASCO 21;2002 2002 [Abstract 551] Riestra, 1998, Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma, J. Clin. Gastroenterol., 26, 200, 10.1097/00004836-199804000-00010 Perrone, 2002, Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial, Curr. Pharm. Des., 8, 1013, 10.2174/1381612024607063 Colleoni, 1995, Megestrol acetate in unresectable hepatocellular carcinoma, Tumori, 81, 351, 10.1177/030089169508100509 Villa, 2001, Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors, Br. J. Cancer, 84, 881, 10.1054/bjoc.2000.1534 Mantovani, 1998, Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate, Semin. Oncol., 25, 45 Negro, 1994, Detection of human androgen receptor mRNA in hepatocellular carcinoma by in situ hybridisation, Liver, 14, 213, 10.1111/j.1600-0676.1994.tb00076.x Guy, 1973, Androgenic steroids and hepatocellular carcinoma, Lancet, 1, 148, 10.1016/S0140-6736(73)90212-2 Nagasue, 1996, Inhibition of growth and induction of TGF-beta 1 in human hepatocellular carcinoma with androgen receptor by cyproterone acetate in male nude mice, J. Hepatol., 25, 554, 10.1016/S0168-8278(96)80216-9 Grimaldi, 1998, Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial, J. Clin. Oncol., 16, 411, 10.1200/JCO.1998.16.2.411 Manesis, 1995, Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial, Hepatology, 21, 1535 Chao, 1996, Phase II study of flutamide in the treatment of hepatocellular carcinoma, Cancer, 77, 635, 10.1002/(SICI)1097-0142(19960215)77:4<635::AID-CNCR8>3.0.CO;2-F Forbes, 1987, Response to cyproterone acetate treatment in primary hepatocellular carcinoma is related to fall in free 5 alpha-dihydrotestosterone, Eur. J. Cancer Clin. Oncol., 23, 1659, 10.1016/0277-5379(87)90446-9 Grosh W, Mueller S, Alexander BF, Caldwell S, Cohen R. Anastrozole (A) treament of patients IPTS) with advanced unresectable hepatocellular carcinoma (HCC). Proc Annu Meet Am Soc Clin Oncol [Abstract 1096] Radaeva, 2002, Interferon-alpha activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes, Gastroenterology, 122, 1020, 10.1053/gast.2002.32388 Sachs, 1985, Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: a pilot study, Br. J. Cancer, 52, 105, 10.1038/bjc.1985.156 The Gastrointestinal Tumor Study Group. A prospective trial of recombinant human interferon alpha2B in previously untreated patients with hepatocellular carcinoma. Cancer 1990;66(1):135–9 Yoshida, 1990, Phase II trial of high dose recombinant gamma-interferon in advanced hepatocellular carcinoma, Eur. J. Cancer, 26, 545, 10.1016/0277-5379(90)90040-Z Lai, 1989, Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial, Br. J. Cancer, 60, 928, 10.1038/bjc.1989.392 Lai, 1993, Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial, Hepatology, 17, 389, 10.1002/hep.1840170307 Llovet, 2000, Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma, Hepatology, 31, 54, 10.1002/hep.510310111 Kubo, 2001, Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial, Ann. Int. Med., 134, 963, 10.7326/0003-4819-134-10-200105150-00010 Ikeda, 2000, Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer, Hepatology, 32, 228, 10.1053/jhep.2000.9409 Feun, 1994, A phase II trial of recombinant leukocyte interferon plus doxorubicin in patients with hepatocellular carcinoma, Am. J. Clin. Oncol., 17, 393, 10.1097/00000421-199410000-00007 Kardinal, 1993, Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma, Cancer, 71, 2187, 10.1002/1097-0142(19930401)71:7<2187::AID-CNCR2820710704>3.0.CO;2-J Bokemeyer, 1995, No synergistic activity of epirubicin and interferon-alpha 2b in the treatment of hepatocellular carcinoma, Cancer Chemother. Pharmacol., 35, 334, 10.1007/BF00689454 Lotz, 1994, Treatment of unresectable hepatocellular carcinoma with a combination of human recombinant alpha-2b interferon and doxorubicin: results of a pilot study, Eur. J. Cancer, 30A, 1319, 10.1016/0959-8049(94)90181-3 Kountouras, 1995, Recombinant a2 interferon (a-IFN) with chemo-hormonal therapy in patients with hepatocellular carcinoma (HCC, Hepatogastroenterology, 42, 31 Brook, 1987, Human lymphoblastoid interferon does not increase survival when added to mitozantrone in the treatment of hepatocellular carcinomas, Aliment. Pharmacol. Ther., 1, 315, 10.1111/j.1365-2036.1987.tb00631.x Colleoni, 1993, A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma, Cancer, 72, 3196, 10.1002/1097-0142(19931201)72:11<3196::AID-CNCR2820721111>3.0.CO;2-Q Komorizono, 2003, Systemic combined chemotherapy with low dose of 5-fluorouracil, cisplatin, and interferon-alpha for advanced hepatocellular carcinoma: a pilot study, Dig. Dis. Sci., 48, 877, 10.1023/A:1023035109665 Feun, 2003, Recombinant leukocyte interferon, doxorubicin, and 5-FUDR in patients with hepatocellular carcinoma-A phase II trial, J. Cancer Res. Clin. Oncol., 129, 17, 10.1007/s00432-002-0398-2 Stuart, 1996, 5-Fluorouracil and alpha-interferon in hepatocellular carcinoma, Am. J. Clin. Oncol., 19, 136, 10.1097/00000421-199604000-00009 Ji, 1996, Combined cis-platinum and alpha interferon therapy of advanced hepatocellular carcinoma, Korean J. Intern. Med., 11, 58, 10.3904/kjim.1996.11.1.58 Kaneko, 2002, Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis, Oncology, 62, 69, 10.1159/000048279 Patt, 2003, Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma, J. Clin. Oncol., 21, 421, 10.1200/JCO.2003.10.103 Iwashita, 2003, A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer, Cancer Immunol. Immunother., 52, 155, 10.1007/s00262-002-0360-9 Haruta, 1996, Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: comparison between LAK cell and CTL therapy, J. Immunother. Emphasis Tumor Immunol., 19, 218, 10.1097/00002371-199605000-00006 Reinisch, 2002, Prospective pilot study of recombinant granulocyte-macrophage colony-stimulating factor and interferon-gamma in patients with inoperable hepatocellular carcinoma, J. Immunother., 25, 489, 10.1097/00002371-200211000-00005 Aldeghi, 1994, Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma, Eur. J. Cancer, 30A, 167, 10.1016/0959-8049(94)90080-9 Meyskens, 1998, Phase II trial of oral beta-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157), Invest. New Drugs, 16, 171, 10.1023/A:1006032706362 Feun, 2003, Thalidomide as palliative care for patients with unresectable hepatocellular carcinoma, Proc. Annu. Meet. Am. Soc. Clin. Oncol., 22 Lin A, Brophy N, Fisher GA, et al. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Proc Annu Meet Am Soc Clin Oncol [Abstract 2202] Kong HL, Boyer MJ, Lim R, Clarke S, Millward MJ, Wong JEL. Phase II trial of thalidomide in unresectable hepatocellular carcinoma: a Cancer Therapeutics Research Group study. Proc Annu Meet Am Soc Clin Oncol [Abstract 2282] Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of Thalidomid for treatment of non-resectable hepatocellular carcinoma. Proc Annu Meet Am Soc Clin Oncol [Abstract 1035] Chen, 2002, A pilot study of celecoxib combined with escalating doses of thalidomide for treatment of unresectable hepatocellular carcinoma, Proc. Annu. Meet. Am. Soc. Clin. Oncol. Treiber, 2003, Palliative treatment of hepatocellular carcinoma (HCC) using octreotide, rofecoxib, or both, Proc. Annu. Meet. Am. Soc. Clin. Oncol., 22, 319 Burris, 1997, Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil, Eur. J. Cancer, 33, S18, 10.1016/S0959-8049(96)00324-3 Kane, 2002, New immunization initiatives and progress toward the global control of hepatitis B, Curr. Opin. Inf. Dis., 15, 465, 10.1097/00001432-200210000-00002 Lin, 2003, Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: sixteen years after newborn vaccination program in Taiwan, J. Med. Virol., 69, 471, 10.1002/jmv.10333 Koff, 2003, Hepatitis vaccines: recent advances, Int. J. Parasitol., 33, 517, 10.1016/S0020-7519(03)00065-1 Wun, 2003, Alpha-fetoprotein and/or liver ultrasonography for liver cancer screening in patients with chronic hepatitis B, Cochrane Database Syst. Rev., 3, 3